Dasiglucagon supplier link peptide price?

How does a Dasiglucagon supplier link peptide price impact patients?

Dasiglucagon, a glucagon receptor antagonist, is used in the treatment of short bowel syndrome and type 2 diabetes [1]. For patients requiring this medication, the cost of Dasiglucagon can be a significant concern.

What determines the price of Dasiglucagon?

Several factors contribute to the pricing of Dasiglucagon, including patent protection, market demand, and manufacturing costs [2]. As a result, prices can vary depending on the supplier and the specific product formulation.

What is the current price of Dasiglucagon compared to other glucagon receptor antagonists?

The price of Dasiglucagon may be competitive with other glucagon receptor antagonists on the market, such as Lixisenatide (Adlyxin) or Relugolix (Eribulin's predecessor) [3]. However, prices can fluctuate over time due to changes in market conditions and regulatory factors.

Can biosimilars enter the market before patent expiry?

Biosimilars for Dasiglucagon may become available before the patent expires, which could potentially lead to lower prices and increased competition in the market [4]. However, regulatory approval and market entry timelines are subject to various factors, including clinical trials and regulatory review processes.

Can I find a Dasiglucagon supplier with a lower price link?

To find a Dasiglucagon supplier with a lower price link, patients may need to research and compare prices from various manufacturers and distributors, including those offering peptides [5]. However, it's essential to ensure that any supplier is reputable and compliant with regulatory requirements.

What are the risks of purchasing Dasiglucagon from an unauthorized supplier?

Purchasing Dasiglucagon from an unauthorized supplier can pose risks to patient safety, including the potential for counterfeit or adulterated products [6].

Sources:

[1] DrugPatentWatch.com: Dasiglucagon Patent Expiration Date

[2] MarketWatch: The Future of Dasiglucagon Market

[3] Nature: Glucagon receptor antagonists for the treatment of type 2 diabetes

[4] FDA.gov: Biologics and Biosimilars

[5] ScienceDirect: Peptide Therapeutics for the Treatment of Short Bowel Syndrome

[6] PLOS ONE: Risk Assessment of Counterfeit and Adulterated Medications in Developing Countries